Table 3.
Risk factors associated with overall survival
| Univariate | Multivariate | |||||||
|---|---|---|---|---|---|---|---|---|
| No. of patients | Follow up (years) | No. of events | Rate | HR | p | HR (95% CI) | p-value | |
| Total | 3279 | 6968 | 142 | 2.04 | ||||
| Sex | ||||||||
| Male | 2307 | 4992 | 105 | 2.10 | ||||
| Female | 972 | 1976 | 37 | 1.87 | 0.89 | 0.527 | 1.07 (0.73, 1.57) | 0.732 |
| Age at entry of TAHOD (years) | ||||||||
| < = 30 | 1103 | 2270 | 40 | 1.76 | ||||
| 31~40 | 1401 | 3016 | 50 | 1.66 | 0.95 | 0.812 | 0.86 (0.57, 1.32) | 0.497 |
| 41+ | 775 | 1682 | 52 | 3.09 | 1.78 | 0.006 | 1.79 (1.18, 2.71) | 0.006 |
| Reported mode of infection | ||||||||
| Heterosexual contact | 2288 | 5013 | 97 | 1.94 | ||||
| Homosexual contact | 614 | 1261 | 12 | 0.95 | 0.47 | 0.014 | 0.68 (0.21, 1.25) | 0.368 |
| Injecting drug use | 132 | 276 | 14 | 5.08 | 2.54 | 0.001 | 1.40 (0.27, 2.53) | 0.772 |
| Blood products | 120 | 196 | 7 | 3.58 | 1.77 | 0.144 | 1.57 (0.26, 3.44) | 0.721 |
| Other/unknown | 125 | 222 | 12 | 5.40 | 2.65 | 0.001 | 1.63 (0.12, 3.01) | 0.883 |
| CD4 count (cells/μL) * | ||||||||
| < = 50 | 316 | 268 | 51 | 19.02 | ||||
| 51–100 | 325 | 246 | 16 | 6.49 | 0.35 | <0.001 | 0.37 (0.21, 0.66) | 0.001 |
| 101–200 | 939 | 875 | 20 | 2.29 | 0.12 | <0.001 | 0.14 (0.08, 0.24) | <0.001 |
| 201–300 | 1238 | 1276 | 19 | 1.49 | 0.08 | <0.001 | 0.10 (0.06, 0.17) | <0.001 |
| 301+ | 2242 | 4244 | 22 | 0.52 | 0.03 | <0.001 | 0.04 (0.02, 0.07) | <0.001 |
| Not tested | 68 | 59 | 14 | 23.68 | 1.18 | 0.592 | 0.86 (0.46, 1.58) | 0.622 |
| Country of TB burden | ||||||||
| High | 1990 | 3775 | 95 | 2.52 | ||||
| Low/intermediate | 1289 | 3193 | 47 | 1.47 | 0.62 | 0.007 | 0.86 (0.60, 1.26) | 0.435 |
| Antiretroviral treatment * | ||||||||
| No treatment | 830 | 1006 | 44 | 4.37 | ||||
| Treated, 0~90 days | 475 | 88 | 8 | 9.14 | 1.89 | 0.103 | 1.08 (0.50, 2.35) | 0.846 |
| Treated, 91–180 days | 703 | 154 | 5 | 3.24 | 0.67 | 0.405 | 0.39 (0.15, 0.99) | 0.049 |
| Treated, 181–360 days | 1048 | 428 | 21 | 4.91 | 1.06 | 0.838 | 0.73 (0.42, 1.27) | 0.265 |
| Treated 361+ days | 2478 | 5292 | 64 | 1.21 | 0.31 | <0.001 | 0.32 (0.21, 0.51) | <0.001 |
| Disease stage * | ||||||||
| CDC Category A | 1444 | 2900 | 37 | 1.28 | ||||
| CDC Category B | 442 | 824 | 12 | 1.46 | 1.15 | 0.679 | 0.95 (0.49, 1.84) | 0.886 |
| TB only | 328 | 634 | 13 | 2.05 | 1.65 | 0.122 | 1.53 (0.80, 2.91) | 0.197 |
| TB + CDC Category B | 202 | 382 | 8 | 2.09 | 1.70 | 0.175 | 0.99 (0.45, 2.16) | 0.976 |
| Single non-TB ADI | 523 | 1035 | 22 | 2.13 | 1.69 | 0.051 | 1.40 (0.80, 2.42) | 0.237 |
| Multiple non-TB ADIs | 212 | 461 | 19 | 4.12 | 3.34 | <0.001 | 2.27 (1.25, 4.10) | 0.007 |
| TB and other ADI(s) | 336 | 732 | 31 | 4.23 | 3.57 | <0.001 | 2.12 (1.27, 3.55) | 0.004 |
Rate: per 100 person years. HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.
* Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the total number of patients.